Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: BioReference Laboratories, Adaptive Biotechnologies, Thermo Fisher Scientific, and More

NEW YORK – Somos, a New York City-based physician-led network, announced that it has selected BioReference Laboratories as a preferred provider for diagnostic testing and to assist with patient-centered data analytics for Somos providers.

The Somos physician-led network consists of more than 2,500 healthcare providers serving more than 700,000 Medicaid beneficiaries in New York City, who are part of predominantly underserved patient populations, Somos said.

As part of the strategic collaboration, Elmwood Park, New Jersey-based BioReference will provide real-time and historical laboratory data to aid in patient diagnosis and case management.

Adaptive Biotechnologies this week announced the closing of its initial public offering of 15 million shares of common stock and the exercise in full of the underwriters' option to purchase 2.25 million additional shares at a public offering price of $20 per share. Gross proceeds from the offering were approximately $345 million before deducting underwriting discounts and commissions and estimated offering expenses. Adaptive's shares began trading on Nasdaq on June 27 under the ticker symbol ADPT.

Thermo Fisher Scientific said on June 28 that it has completed the sale of its Anatomical Pathology business to global healthcare company PHC Holdings for approximately $1.14 billion in cash. The deal was originally announced in January. The Anatomical Pathology business has approximately 1,200 employees in the US, Europe, and Asia and generated approximately $350 million in annual revenue. It was part of Thermo Fisher's Specialty Diagnostics business segment.

TATAA Biocenter said this week that it will distribute MethylDetect's DNA methylation assays in Scandinavia and the Czech and Slovak Republics. MethylDetect's assays are based on methylation-sensitive high-resolution melting technology and offer high specificity and sensitivity, TATAA said. The assays will also be used in TATAA's accredited molecular analysis services and training courses, the center said.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.